In Vitro Diagnostics Business Outlook, Volume 3, Issue 4 - Blood Screening
ISSUE 4 OF 6 - In Vitro Diagnostics Business Outlook, Volume 3, Issue 4 - Blood Screening
In Vitro Diagnostics Business Outlook offers information and data that you cannot get anywhere else, including:
Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
- A comprehensive view of the IVD market with test categories covered and company briefs
- M&A activities, selected partnerships & collaborations, partnership deals, and more
- Industry & region watch to help tailor strategies
- Analysis of news and events and reporting on news not easily available
- MARKET ANALYSIS: FOCUS ON BLOOD SCREENING DIAGNOSTICS
- OVERVIEW OF BLOOD SCREENING
- MARKET OUTLOOK
- Figure: Blood Screening Market, 2019-2029 ($ billion)
- Figure: Blood Screening Sales, by Test Method, 2024 and 2029 ($ billion) (Immunoassay Screen, NAT Screens)
- Figure: Blood Donation Screening Market Distribution, by Analyte, 2024 (%) (Hepatitis, HIV, Other)
- REGIONAL MARKET
- Table: Estimated Blood Donations, by WHO Region, 2018
- Figure: Whole Blood Donations per 1000 Population, 2018
- Table: Blood Screening Market Distribution, by Global Region, 2024 (%) (Asia Pacific, Europe, North America, RoW)
- Figure: Blood Screening Market Distribution of Sales, by Global Region (%) (Asia Pacific, Europe, North America, RoW)
- Segment Activity by Region
- Immunoassays
- Figure: Market Summary: Immunoassay Blood Screening Market, Distribution of Sales, by Region, 2024 (%) (Asia Pacific, Europe, North America, RoW)
- Molecular
- Figure: Market Summary: NAT Blood Screening Market, Distribution of Sales by Region (North America, Europe, Asia Pacific, RoW), 2024
- TOP COMPANY BRIEFS
- Roche
- Grifols
- Abbott
- EXECUTIVE NEWS BRIEFING
- BRIEFS
- Trinity Biotech Engages New CCO
- BillionToOne Closes Financing Deal
- OraSure Technologies Elects New Board Member
- Viome Life Sciences Secures $25 Million in Financing
- Syantra Raises $3.6 Million in A-1 Round Financing
- FINANCIAL HIGHLIGHTS: DEXCOM AND EXACT SCIENCES
- Dexcom Revenues Increase 15% (+$133 million) in Q2 2024
- Figure: Dexcom Revenue Mix, by Product Segment, Q2 2023 and Q2 2024
- Figure: Dexcom Revenue Mix by Product Segment, By Quarter 2022 – Q2 2024
- Table: Dexcom Geographic Revenues, by Region, Q2 2023 and Q2 2024 ($ million)
- Exact Sciences Reports it “Tested a Record Number of Cancer Patients with Oncotype DX”
- Figure: Exact Sciences Revenue Mix, by Product Segment, Q2 2023 vs Q2 2024 ($ million)
- Figure: Exact Sciences Revenue Mix, by Product Segment, by Quarter 2022-Q2 2024 ($ million)
- DIAGNOSTIC MARKET MERGERS, ACQUISITIONS AND PARTNERSHIP DEALS
- PARTNERSHIPS AND COLLABORATIONS
- MERGERS AND ACQUISITIONS
- Table: Selected Diagnostic Market Mergers and Acquisitions Deals
- REGION WATCH
- Figure: South Korea GDP, GDP (PPP), and Health Spending, CAGR 2005-2010, 2010-2015, 2015-2020 and 2020-2023 (%)
- Figure: South Korea Medical Tourism Visits Reported, 2009-2023 (# of patients)
- Figure: South Korea Old-Age Dependency Ratio and Aging Index, 1980-2065
- BROAD-BASED COMPANY ANNOUNCEMENTS
- ANNOUNCEMENTS
- Foundation Medicine Gets the Nod for Its Companion Diagnostics
- QuidelOrtho Proud to Announce Clearance for VITROS Syphilis Assay
- AliveDx Receives IVDR-CE Mark for Multiplexed Assay
- T2 Biosystems Scores FDA Pediatric Clearance
- ID-FISH Technology Announces FDA Nod for its Lyme ImmunoBlot
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook